No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is metabolised to an active metabolite, fenofibric acid: in vitro data suggest that fenofibric acid inhibits OAT3. A clinically relevant drug interaction is unlikely as emtricitabine and tenofovir are mainly excreted by different renal transporters.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking